Tenderwize
Retour à la recherche

Open house drug discount agreements Risankizumab, ATC L04AC18

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Oct 03, 2027 · 400 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Risankizumab, ATC L04AC18

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

The open-house model does not guarantee any minimum purchase volume; revenue depends on actual prescriptions.

If a non-exclusive discount contract for the same substance is concluded via a public procurement, this open-house agre...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Non-exclusive discount agreements for pharmaceutical products containing Risankizumab (ATC L04AC18)
  • Contracts are identical and non-negotiable for all participants
Afficher le résumé complet

This is an open-house procedure by AOK Bayern for non-exclusive discount agreements on Risankizumab (ATC L04AC18) under §130a SGB V. It is not a public procurement but a voluntary participation model open to all pharmaceutical companies that meet eligibility criteria. Contracts can be concluded anytime until 03.10.2027, with a minimum term until 30.11.2027. No estimated value or award criteria are defined; all eligible participants receive a contract.

Risques

The open-house model does not guarantee any minimum purchase volume; revenue depends on actual prescriptions.

If a non-exclusive discount contract for the same substance is concluded via a public procurement, this open-house agre...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Submit a signed declaration of reliability
  • Submit the signed contract and annex 'Determination of the contract-related medicinal products'

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria - open house model, all eligible participants get a contract.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements Risankizumab, ATC L04AC18

Non-exclusive discount agreements for the active substance Risankizumab, ATC L04AC18, in Germany. Contract term from 01.12.2025 to 30.11.2027. No selection process; all pharmaceutical companies meeting eligibility can join.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Nov 2025 - Nov 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria - open house model, all eligible participants get a contract.

Date limite

Deadline Oct 03, 2027

Détails de la procédure

Date de publication
13 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
675355-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30